Market research
ANPC Anpac Bio Medical Science Co Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 8
- Dividend yield
- 0.0%
- Beta
- 1.56
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US03635R1077
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 8
- Dividend yield
- 0.0%
- Beta
- 1.56
About
About Anpac Bio Medical Science Co Ltd
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. It also offers physical checkup packages, as well as technology services comprising market research, designing, coding, developing, testing, etc. In addition, the company sells genetic testing kits and skin-care products; and owns core technology platforms, as well as engages in technology development and product distribution. The company was formerly known as AnPac Bio-Medical Science Co., Ltd. and changed its name to Fresh2 Group Limited in April 2023. The company was incorporated in 2010 and is headquartered in Shanghai, the People's Republic of China.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ANPC discussion.
5 years, 4 months ago
AnPac Bio-Medical Science Co., Ltd is currently in a long term downtrend where the price is trading 19.4% below its 200 day moving average.
From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 40.6.
Based on the above factors, AnPac Bio-Medical Science Co., Ltd gets an overall score of 1/5.